Literature DB >> 2890911

Is "improvement" real with percutaneous transluminal angioplasty in the management of renovascular hypertension?

L A Brawn1, L E Ramsay.   

Abstract

58 hypertensive patients with suspected renovascular disease underwent renal arteriography, and 29 (52%) were found to have renovascular disease. Percutaneous transluminal angioplasty was technically successful in 14 (50%) of the 29. The effect on blood pressure was assessed over 20 months. Technically successful transluminal angioplasty led to cure of hypertension in 4 patients (29%) and "improvement" in 5 (36%). However, "improvement" occurred spontaneously in 8 (32%) of the 25 patients found on arteriography not to have renovascular disease and who received no intervention. This suggests that reported improvement after transluminal angioplasty may be spurious and that the true benefit of the procedure can be assessed only from the cure rate. About 50% of patients with fibromuscular renovascular disease are cured of their hypertension but only about 8% of patients with atherosclerotic renovascular disease benefit from the procedure.

Entities:  

Mesh:

Year:  1987        PMID: 2890911     DOI: 10.1016/s0140-6736(87)91203-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series.

Authors:  L E Ramsay; P C Waller
Journal:  BMJ       Date:  1990-03-03

2.  Midterm results of renal artery stenting.

Authors:  F Joffre; H Rousseau; P Bernadet; C Nomblot; J C Montoy; R Chemali; C Knight
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

3.  Clinical efficacy of percutaneous renal revascularization with stent placement in hypertension among patients with atherosclerotic renovascular diseases.

Authors:  Seyed Mohammad Hassan Adel; Seyed Masood Syeidian; Mohammad Najafi; Mohammad Nourizadeh
Journal:  J Cardiovasc Dis Res       Date:  2011-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.